SAN DIEGO (AP) _ Conatus Pharmaceuticals Inc. (CNAT) on Thursday reported a loss of $4.6 million in its third quarter.
The San Diego-based company said it had a loss of 15 cents per share.
The results matched Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was also for a loss of 15 cents per share.
The biotechnology company posted revenue of $7.7 million in the period, which did not meet Street forecasts. Five analysts surveyed by Zacks expected $9.7 million.
The company's shares closed at $4.28. A year ago, they were trading at $4.51.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CNAT at https://www.zacks.com/ap/CNAT